Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
16.06
-0.15 (-0.93%)
May 29, 2026, 4:00 PM EDT - Market closed
Theravance Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 109.78 | 107.46 | 64.38 | 57.42 | 51.35 | 55.31 | |
Revenue Growth (YoY) | 68.20% | 66.92% | 12.12% | 11.84% | -7.17% | -23.03% |
Gross Profit | 109.78 | 107.46 | 64.38 | 57.42 | 51.35 | 55.31 |
Selling, General & Admin | 73 | 73.65 | 69.17 | 70.1 | 67.07 | 99.3 |
Research & Development | 31.79 | 37.41 | 37.64 | 40.62 | 63.39 | 193.66 |
Other Operating Expenses | 3.63 | - | 4.51 | 2.74 | 12.84 | 20.14 |
Total Operating Expenses | 108.43 | 111.07 | 111.33 | 113.46 | 143.3 | 313.1 |
Operating Income | -18.66 | -3.6 | -46.95 | -56.04 | -91.96 | -257.78 |
Interest Income | 12.25 | 10.17 | 4.88 | 9.12 | 8.55 | 1.11 |
Interest Expense | -1.82 | -2.46 | -2.55 | -2.35 | -6.37 | -8.55 |
Other Non-Operating Income (Expense) | 125.14 | 125.14 | - | - | -3.03 | - |
Total Non-Operating Income (Expense) | 135.57 | 132.85 | 2.34 | 6.77 | -0.86 | -7.44 |
Pretax Income | 143.39 | 129.25 | -44.61 | -49.27 | -92.82 | -265.22 |
Provision for Income Taxes | -8.04 | - | - | - | - | -0.15 |
Net Income | -4.93 | 129.25 | -44.61 | -55.19 | 872.14 | -199.43 |
Earnings From Discontinued Operations | - | - | - | - | 964.96 | 65.65 |
Net Income to Common | -4.93 | 129.25 | -44.61 | -55.19 | 872.14 | -199.43 |
Shares Outstanding (Basic) | 51 | 50 | 49 | 55 | 74 | 69 |
Shares Outstanding (Diluted) | 52 | 52 | 49 | 55 | 74 | 69 |
Shares Change (YoY) | 4.59% | 5.45% | -11.67% | -24.85% | 5.95% | 11.41% |
EPS (Basic) | 2.26 | 2.10 | -1.15 | -1.00 | 11.85 | -2.87 |
EPS (Diluted) | 2.20 | 2.06 | -1.15 | -1.00 | 11.85 | -2.87 |
Shares Outstanding | 51.52 | 51.07 | 49.47 | 48.09 | 65.23 | 74.44 |
Free Cash Flow | 268.76 | 238.5 | -11.87 | -29.49 | -187.56 | -211.26 |
Free Cash Flow Growth | 12.69% | - | - | - | - | - |
Free Cash Flow Per Share | 5.20 | 4.63 | -0.24 | -0.53 | -2.55 | -3.04 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -17.00% | -3.35% | -72.92% | -97.58% | -179.09% | -466.06% |
Profit Margin | 137.94% | 120.27% | -69.30% | -85.80% | -180.76% | -479.24% |
FCF Margin | 244.82% | 221.93% | -18.43% | -51.35% | -365.29% | -381.96% |
EBITDA | -12.96 | 2.04 | -40.83 | -49.88 | -84.25 | -249.2 |
EBITDA Margin | -11.81% | 1.90% | -63.41% | -86.87% | -164.09% | -450.54% |
EBIT | -18.66 | -3.6 | -46.95 | -56.04 | -91.96 | -257.78 |
EBIT Margin | -17.00% | -3.35% | -72.92% | -97.58% | -179.09% | -466.06% |
Effective Tax Rate | -5.61% | 0.00% | 0.00% | 0.00% | 0.00% | 0.06% |